Unlike everyday supplements stocked in every health store, CJC-1295 is distributed via a specialist research supply market that Alice residents reach through online vendors. What this means for Alice researchers is that physical proximity is irrelevant compared to your ability to verify analytical documentation — and those verification methods are accessible to anyone. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. The sections below cover what Alice researchers need to know about sourcing, verifying, and handling CJC-1295 for research purposes.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Alice researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
Vetting CJC-1295 vendors starts with the COA: request the batch-specific certificate before placing an order, not after. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. Community reputation in research forums is a complementary signal to COA verification — vendors with multi-year positive track records have built their reputation on real product performance. Store lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order CJC-1295 — ships to Alice
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the comprehensive clinical trial data that characterises approved medications. Storage requirements for CJC-1295: lyophilised powder at minus 20°C, reconstituted solution refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with sterile bacteriostatic water. Bacterial endotoxin contamination is the most serious safety risk specific to research peptides — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. Protocol documentation — documenting product details, dates, and administration precisely — is a research best practice for CJC-1295 that ensures unusual findings can be explained.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
